This is the authors' abstract. We don't add key points for this paper.
Activity of Glutoxim, a sulfur-containing hexapeptide with immunomodulating effect on lymphocytes, was studied on human neutrophils. Commercial available agent containing the substance, Glutoxim, was used. At the doses of 1, 3, 6 or 100 microg/mL the drug stimulated the superoxide anion and hypochlorous acid generation in resting neutrophils but inhibited them in cells stimulated with zymosan or PMA. The only inhibiting effect was observed on nitric oxide production in LPS-stimulated RAW 264.7 cells. The drug also influenced neutrophil chemotaxis showing chemoattractant activity on cells and inhibiting fMLP-induced chemotaxis. These effects on neutrophils confirm and extend range of Glutoxim immunomodulating abilities.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Fimiani et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: